Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

NEWS Press Release Media Report

Year:

Select

Press Release

10 May 2023

Alphamab Oncology will present updated data on innovative bispecific antibody combination therapy at ASCO 2023 Efficacy and Safety of KN026 in combination with KN046 in Patients with Locally Advanced Unresectable or Metastatic HER2-positive Other Solid Tumors
09 May 2023

IND Application for Phase Ⅲ Registration Study of KN026 in Combination with Chemotherapy for the First-line Treatment of Breast Cancer Was Approved by CDE We will further explore the efficacy and safety of KN026 in combination with docetaxel through this registered clinical trial, in the hope of bringing more effective treatment options to patients with...
17 April 2023

Late-Breaking Research! Alphamab Oncology Presents Preclinical Results of KN052 at AACR 2023 KN052 has acceptable pharmacokinetics and safety, and its antitumor activity is significantly stronger than that of the two single-target control antibodies used alone and in combination.
04 April 2023

Alphamab Oncology Reports Full Year 2022 Financial Results and Business Highlights we will seize the opportunity of commercialization of KN046 to establish an efficient commercial system and accelerate the delivery of innovative products to more patients
16 March 2023

Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003 JSKN003-102 trial and ongoing JSKN003-101 complement with each other, laying the foundation for the global development of JSKN003.
15 March 2023

Alphamab Oncology to Present the Preclinical Results of PD-L1/OX40 Bispecific Antibody KN052 at AACR 2023 Late-Breaking Research: Experimental and Molecular Therapeutics
15 December 2022

Alphamab Oncology Announces Positive Results from an Ongoing Interim Review of Safety and Efficacy Data from Envollizumab (KN035) in a Phase 2 Pivotal Clinical Trial of ENVASARC in the United States Double-Digit Objective Response Rate (ORR) by Central Review Achieved in Each Cohort and the Bar for Futility was Exceeded in Each Cohort
12 December 2022

Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer at SABCS 2022 KN026 demonstrated promising efficacy and well tolerated in combination with docetaxel in patients with early or locally advanced HER2-positive breast cancer
12 December 2022

Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer at SABCS 2022 The median OS was not reached with 12, 18 and 24 months OS rates at 93.0 %, 91.2 % and 91.2 %, respectively.
12 December 2022

Alphamab Oncology Presented Final Analysis of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at SABCS 2022 Both PD-L1 negative and positive patients could derive OS benefit from the therapy.